A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma
Primary Objective:
To evaluate the efficacy of different doses and regimens of dupilumab in participants with moderate to severe uncontrolled asthma.
Secondary Objective:
To evaluate different doses and regimens of dupilumab in participants with moderate to severe uncontrolled asthma, with regard to:
Total duration per participant of approximately 43 weeks including a screening period (14-21 days), a randomized treatment period (24 weeks), and a post-treatment period (16 weeks).
Inclusion criteria:
Participants with a physician diagnosis of moderate to severe, uncontrolled asthma for >=12 months, based on the Global Initiative for Asthma (GINA) 2009 Guidelines and:
Exclusion criteria:
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Caba, 1424, Argentina
Caba, 1425, Argentina
Caba, Argentina
Asahi-Shi, Japan
Chiyoda-Ku, Japan
Chuoh-Ku, Japan
Edogawa-Ku, Japan
Fukuyama-Shi, Japan
Habikino-Shi, Japan
Himeji-Shi, Japan
Hirakata-Shi, Japan
Iizuka-Shi, Japan
Isesaki-Shi, Japan
Itabashi-Ku, Japan
Kitakyushu-Shi, Japan
Kiyose-Shi, Japan
Kodaira-Shi, Japan
Kokubunji-Shi, Japan
Kurashiki-Shi, Japan
Nagaoka-Shi, Japan
Naka-Gun, Japan
Naruto-Shi, Japan
Ohta-Shi, Japan
Sagamihara-Shi, Japan
Sakaide-Shi, Japan
Setagaya-Ku, Japan
Sumida-Ku, Japan
Tomakomai-Shi, Japan
Toride-Shi, Japan
Tsukubo-Gun, Japan